Related Articles
Potential synergistic effects of sorafenib and CP‑31398 for treating anaplastic thyroid cancer with p53 mutations
Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: Characterization of resistant cells
Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status
Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer
Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines